Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien divests part of medical supplies unit

This article was originally published in The Gray Sheet

Executive Summary

Covidien will sell its European incontinence product business to a private French firm for undisclosed terms under a definitive agreement announced Feb. 19. Previously a part of Covidien's struggling medical supplies unit, the divested business had sales of $109 million in fiscal 2007. Last December, Covidien sold its diaper-making retail unit for $335 million (1"The Gray Sheet" Jan. 7, 2008, p. 20)

You may also be interested in...



Covidien Keeps Medical Supplies Unit On Watch List After Sale Of Diaper Biz

Diversified med-tech firm Covidien will continue evaluating potential divestitures following the sale of its diaper-making retail unit, according to the company

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

UsernamePublicRestriction

Register

MT025800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel